Dyne Therapeutics Inc (NASDAQ:DYN) stock climbed 3.6% following the announcement that the U.S. Food and Drug Administration ...

July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment ...

Liberals promised to ‘significantly reduce’ wait times for pharmaceuticals, which it acknowledged were longer than in other ...

The FDA issued another complete response letter for odronextamab for the treatment of relapsed/refractory follicular lymphoma.

United Health Products, Inc. (OTCQB: UEEC) today provided a status update on its discussions with the Food & Drug Administration. As previously disclosed, the Company's Investigational Device ...

Complete Response Letters recently issued by the FDA signal heightened scrutiny of trial design and reinforce the agency’s shifting regulatory expectations for sponsors and CROs.

EuMentis Therapeutics, Inc., ("EuMentis"), a clinical-stage drug development company focused on advancing novel treatments ...

The COA Research and Manufacturing Limited Company (COARMLC) has officially denied claims suggesting that its product, COA-72 ...

The FDA has issued a CRL to Replimmune regarding the BLA for vusolimogene oderparepvec (RP1) in combination with nivolumab for advanced melanoma.

Detailed price information for Replimune Group Inc (REPL-Q) from The Globe and Mail including charting and trades.

The Food and Drug Administration (FDA) has issued another Complete Response Letter (CRL) to Regeneron (CRL) for the Biologics License Application (BLA) for odronextamab in relapsed/refractory ...

In the completed Phase 1/2 EXPLORE44 trial, del-zota demonstrated statistically significant increases in exon skipping, substantial increases in dystrophin production, and a significant reduction in ...